Genocea Biosciences Inc. (NASDAQ:GNCA) traded up 2.7% during trading on Friday . The company traded as high as $4.98 and last traded at $4.95, with a volume of 67,566 shares trading hands. The stock had previously closed at $4.82.

A number of equities research analysts have recently commented on the company. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. FBR & Co reiterated a “buy” rating on shares of Genocea Biosciences in a report on Monday, August 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $17.95.

The stock has a 50 day moving average of $4.33 and a 200-day moving average of $4.33. The stock’s market cap is $142.52 million.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. On average, equities analysts anticipate that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.